Keyphrases
Randomized Trial
100%
Remdesivir
83%
Finland
83%
COVID-19 Infection
83%
Rehospitalization
83%
Imatinib
83%
Hospitalized COVID-19 Patients
83%
Standard of Care
75%
COVID-19
33%
Long COVID Symptoms
33%
Symptomatic Outcome
16%
Confidence Interval
16%
Bother
16%
Focus of Attention
16%
Patient-important Outcomes
16%
1-year Follow-up
16%
Hospitalized Patients
16%
With Memory
16%
Quality of Life Outcomes
16%
Hospitalization
16%
Joint Pain
16%
Quality of Life
16%
Meta-analysis
16%
Quality of Recovery
8%
Sleep Problems
8%
Systematic Meta-analysis
8%
Reduced Mortality
8%
Risk Ratio
8%
Mortality Risk
8%
30-day Mortality
8%
Pharmacology, Toxicology and Pharmaceutical Science
Remdesivir
83%
Infection
83%
Imatinib
83%
Arthralgia
16%
